Prosecution Insights
Last updated: September 17, 2026
Application No. 18/712,511

WEE1 INHIBITOR, PREPARATION THEREFOR, AND USE THEREOF

Non-Final OA §112
Filed
May 22, 2024
Priority
Jan 18, 2022 — CN 202210053373.X +1 more
Examiner
OH, TAYLOR V
Art Unit
Tech Center
Assignee
Jiangsu Tasly Diyi Pharmaceutical Co. Ltd.
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1437 granted / 1769 resolved
+21.2% vs TC avg
Strong +15% interview lift
Without
With
+15.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
56 currently pending
Career history
1793
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
37.1%
-2.9% vs TC avg
§102
17.9%
-22.1% vs TC avg
§112
35.0%
-5.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1769 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Non-Final Rejection The Status of Claims: Claims 1, 16-18 and 21 are pending. Claims 1, 16-18 and 21 are rejected. DETAILED ACTION 1. Claims 1, 16-18 and 21 are under consideration in this Office Action. Priority 2. It is noted that this application is a 371 of PCT/CN2023/070285 01/04/2023 which has a foreign priority document, CHINA CN202210053373.X 01/18/2022. Drawings 3. None. IDS 4. The IDS filed on 5/22/24 and 6/25/26 are reviewed by the examiner. Election/Restriction Applicant’s election without traverse of Group I (claims 1, 16-18 and 21 ) on 7/23/26 is acknowledged. Claims 19-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected group II, which was cancelled currently, there being no allowable generic or linking claim. The elected compound 3 , PNG media_image1.png 107 205 media_image1.png Greyscale is allowable. Claim Objections Claims 16-18 are objected to because of the following informalities: In claims 16-18, there is no period at the end of the claims. This is improper. The examiner recommends to put the period ”.” at the end of each ofthe claims. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 16-18 and 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. In claim 1, the phrases “selected from a group consisting of methyl, ethyl, propyl, …, PNG media_image2.png 41 41 media_image2.png Greyscale ” and “selected from a group consisting of PNG media_image3.png 77 291 media_image3.png Greyscale … PNG media_image4.png 97 87 media_image4.png Greyscale ” and “selected from a group consisting of PNG media_image5.png 127 134 media_image5.png Greyscale , … PNG media_image6.png 124 78 media_image6.png Greyscale ” are recited. These expressions are improper because the Markush expression would require a close ended “and “at the end of each of the limitations. Appropriate correction is required. In claims 16-18, the limitation “ the specific compound represented by formula I is” is recited. This expression can be incomplete and vague because the following list of the compounds are inside the table form, which has no expression of the term”:and “ before the last compound and no period at the end of the claims. The examiner recommends to add the phrase “selected from “ after the limitation “ the specific compound represented by formula I is”. The Close Prior Art The close priorart to the current invention is Marton et al (US 2017/0095479 A1) , which teaches that PNG media_image7.png 252 461 media_image7.png Greyscale can be used as a WEE1 inhibitor to treat cancer. However, this compound is different from the claimed compound with respect to the substituents surrounding the core structure. Therefore, it would have been unobvious over the claimed invention. Conclusion Claims 1, 16-18 and 21 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TAYLOR V OH whose telephone number is (571)272-0689. The examiner can normally be reached 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TAYLOR V OH/Primary Examiner, Art Unit 1625 8/14/2026
Read full office action

Prosecution Timeline

May 22, 2024
Application Filed
May 22, 2024
Response after Non-Final Action
Aug 18, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735427
SUGAR DERIVED LIPID NANOMATERIALS AND USES THEREOF
3y 1m to grant Granted Sep 15, 2026
Patent 12735413
TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K
2y 11m to grant Granted Sep 15, 2026
Patent 12728124
NEW MEDICAL USE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATORS
3y 6m to grant Granted Sep 08, 2026
Patent 12729183
PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR
3y 8m to grant Granted Sep 08, 2026
Patent 12729187
OXIDATIVE PRETREATMENT OF CARBOHYDRATE DEHYDRATION PRODUCTS COMPRISING HUMINS
3y 5m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
96%
With Interview (+15.3%)
2y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1769 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month